BPH, is caused due to enlargement of the prostate gland and commonly affects the ageing male population. Over 50% of men above the age of 60 and around 80% beyond the age of 80, suffer from BPH worldwide. “If left untreated, BPH can lead to serious health problems, including urinary tract infections, bladder and kidney damage, bladder stones and inability to hold urine,” it added.

“The launch of Flotral further expands Ranbaxy’s key strategic product portfolio and establishes the company’s commitment to build its urology franchise through its competitive edge technology of NDDS,” Sanjeev I Dani, regional director-India, Ranbaxy, stated.

Ranbaxy Laboratories Limited, India's largest Rx pharmaceutical company, manufactures and markets branded generic drugs and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 34 countries and manufacturing operations in 7 countries.